Literature DB >> 23357768

Pharmacokinetic and pharmacodynamic evaluation of P-873 versus Klebsiella pneumoniae in a neutropenic murine thigh infection model.

Lucinda M Lamb1, Jared L Crandon, David P Nicolau.   

Abstract

P-873 is a novel compound in the RX-04 pyrrolocytosine series of protein synthesis inhibitors currently under development by Rib-X Pharmaceuticals. We evaluated the pharmacodynamic and pharmacokinetic properties of this compound against Klebsiella pneumoniae using a murine neutropenic thigh infection model. P-873 demonstrated potent and rapid in vivo activity against this organism with enhanced penetration and duration of exposure in thigh tissue.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23357768      PMCID： PMC3623370          DOI： 10.1128/AAC.02170-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Authors:  Brad Spellberg; Robert Guidos; David Gilbert; John Bradley; Helen W Boucher; W Michael Scheld; John G Bartlett; John Edwards
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 2.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

3.  In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.

Authors:  Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191
  3 in total
  3 in total

1.  In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

Authors:  Robert K Flamm; Paul R Rhomberg; Ronald N Jones; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.

Authors:  Anna Vickers; Shazad Mushtaq; Neil Woodford; Michel Doumith; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

3.  RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.

Authors:  Julien M Buyck; Frédéric Peyrusson; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.